MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

MAIA Biotechnology (NYSEAMERICAN:MAIA) posted its quarterly earnings data on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01, FiscalAI reports.

MAIA Biotechnology Trading Up 2.8%

MAIA Biotechnology stock traded up $0.03 during midday trading on Monday, reaching $1.09. 226,201 shares of the stock traded hands, compared to its average volume of 722,915. The firm has a market cap of $67.30 million, a PE ratio of -1.76 and a beta of 0.28. The company has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.45. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $3.19.

Insider Transactions at MAIA Biotechnology

In other MAIA Biotechnology news, CEO Vlad Vitoc purchased 73,000 shares of MAIA Biotechnology stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of $1.37 per share, with a total value of $100,010.00. Following the completion of the transaction, the chief executive officer owned 1,049,121 shares of the company’s stock, valued at $1,437,295.77. This trade represents a 7.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ramiro Guerrero acquired 37,595 shares of the stock in a transaction dated Thursday, September 10th. The stock was acquired at an average cost of $1.32 per share, with a total value of $49,625.40. Following the purchase, the director owned 773,296 shares of the company’s stock, valued at approximately $1,020,750.72. This trade represents a 5.11% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 258,078 shares of company stock worth $352,426 over the last quarter. Insiders own 19.81% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.